Llanes Elmer Jasper B, Thongtang Nuntakorn, Lee Zhen-Vin, Hoa Tran, Yee Ong Hean, Sukmawan Renan
Division of Cardiovascular Medicine, University of the Philippines, Philippine General Hospital, Philippines.
Division of Endocrinology and Metabolism, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand.
Am J Prev Cardiol. 2025 Jun 2;23:101019. doi: 10.1016/j.ajpc.2025.101019. eCollection 2025 Sep.
Statin therapy, known for its lipid-lowering properties, substantially lowers the risk of cardiovascular events in patients vulnerable to atherosclerotic cardiovascular disease (ASCVD) across diverse demographic groups. Despite evidence supporting their benefits, statins are often underutilized or even discontinued. Disparities in statin utilization exist across Asian countries due to healthcare system policies and economic circumstances. Addressing these disparities is essential, especially in the context of global initiatives designed to enhance affordability and raise awareness. Healthcare practitioners (HCPs) must assess ASCVD risks and take proactive measures aimed at lowering these risks, particularly through the management of low-density lipoprotein cholesterol (LDL-C) levels. It is imperative for HCPs and patients to collaborate for effective management of ASCVD risk, prioritizing improved adherence, treatment continuity, and better health outcomes. This review focuses on statin utilization and adherence in six Asian countries-Thailand, Malaysia, Philippines, Vietnam, Singapore, and Indonesia. It aims to explore the common factors that influence long-term adherence to statin treatment and also offers practical recommendations to improve adherence, ultimately leading to better cardiovascular outcomes in the Asian population.
他汀类药物疗法以其降血脂特性而闻名，能大幅降低易患动脉粥样硬化性心血管疾病（ASCVD）的不同人群发生心血管事件的风险。尽管有证据支持他汀类药物的益处，但它们常常未得到充分利用，甚至被停用。由于医疗体系政策和经济状况，亚洲国家在他汀类药物使用方面存在差异。解决这些差异至关重要，特别是在旨在提高可及性和提高认知度的全球倡议背景下。医疗从业者（HCPs）必须评估ASCVD风险，并采取积极措施降低这些风险，特别是通过管理低密度脂蛋白胆固醇（LDL-C）水平。HCPs和患者必须合作，以有效管理ASCVD风险，优先提高依从性、治疗连续性并改善健康结果。本综述聚焦于泰国、马来西亚、菲律宾、越南、新加坡和印度尼西亚这六个亚洲国家的他汀类药物使用和依从性。其目的是探索影响他汀类药物长期治疗依从性的常见因素，并提供提高依从性的实用建议，最终改善亚洲人群的心血管结局。
